Aclaris Therapeutics Inc (ACRS) Actualités

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

- Progressing ATI-2138 into Atopic Dermatitis -- Management to Host Conference Call at 5:00 PM ET Today...

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage...

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer PR Newswire CAMBRIDGE...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]